Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q1 FY24 Earnings Presentation
32 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, Aug 14, 2023
Slide 1: IOL Chemicals and Pharmaceuticals Limited Q1FY24 Investor Presentation
IOL Chemicals and Pharmaceuticals Limited Q1FY24 Investor Presentation August 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by IOL Chemicals & Pharmaceuticals Limited (the “Companies”, IOL) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on i
Slide 3: Table of Contents
Table of Contents 01 IOLCP at a glance 02 Financial Highlights 03 Company Overview Quarterly Income Statement The Journey About IOL Chemicals and Pharmaceuticals Ltd. Growing top-line Core management team Q1FY24 Performance Building Assets Board of Directors Geographical & Segmental Highlights Cash
Slide 4: IOL Chemicals & Pharma - Overview
IOL Chemicals & Pharma - Overview Incorporated in 1986, IOLCP is one of the leading API Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Team size of 2700+ employees Credit Rating: A+, outlook; stable (Care Ratings Limited) Debt free
Slide 5: Q1FY24 Performance
Q1FY24 Performance Operational Highlights Q1FY24 Financial Performance • CARE Rating has reaffirmed to A+ with a stable outlook 570.24 79.92 14% • Commenced plant for Acetic Anhydride, which Revenues (Rs. cr) EBITDA (Rs. cr) EBITDA Margin shall be used for captive consumption as well as merchant sal
Slide 6: Geographical and Segmental highlights
Geographical and Segmental highlights Chemical Segment (Rs. crore) Pharma Segment (Rs. crore) 279 400 368 100 300 16 349 238 303 303 250 218 219 214 12 300 285 80 80 200 60 8 150 13 200 11 50 40 10 4 100 100 -1 33 35 20 0 50 -3 24 0 0 0 -4 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q1FY23 Q2FY23 Q3FY23 Q4FY
Slide 7: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 8: Quarterly Income Statement
Quarterly Income Statement Particulars (Rs. Cr) Q1 FY24 Q1 FY23 YoY Q4 FY23 Revenues 563.2 565.0 587.2 Other Income 7.1 5.2 8.7 Total Income 570.3 570.2 595.9 Total Expenses 490.4 509.0 491.4 EBITDA 79.9 61.2 30.6% 104.5 EBITDA Margin (%) 14.0% 10.7% 330 bps 17.5% Depreciation 14.4 11.0 12.1 Finance
Slide 9: Yearly Income Statement
Yearly Income Statement Particulars (Rs. Cr) FY23 FY22 YoY Revenues 2,217.1 2,184.0 Other Income 25.6 32.0 Total Income 2,242.7 2,216.0 1.2% Total Expenses 1,990.6 1,927.6 EBITDA 252.1 288.4 -12.6% EBITDA Margin (%) 11.2% 13.0% -180 bps Depreciation 46.1 43.3 Finance Cost 16.5 8.3 Profit Before Exce
Slide 10: Growing top-line
Growing top-line Particulars (Rs. Cr) FY18 FY19 FY20 FY21 FY22 FY23 Revenues 983.3 1,685.3 1,894.5 1,967.0 2,184.0 2,217.1 Other Income 6.3 10.4 16.0 24.3 32.0 25.6 Total Income 989.6 1,695.7 1,910.5 1,991.3 2,216.0 2,242.7 Total Expenses 863.7 1,275.7 1,320.6 1,375.2 1,927.6 1,990.6 EBITDA 125.9 42
Slide 11: Building assets
Building assets Balance Sheet (Rs. Cr) FY18 FY19 FY20 FY21 FY22 FY23 Shareholders' Funds 215.7 474.3 813.5 1260.4 1390.3 1506.6 Debt 421.9 284.0 56.0 0.0 0.0 0.0 Total Non-current Liabilities 33.6 20.8 79.7 59.1 56.6 58.1 Total Current Liabilities 180.9 162.8 220.6 290.6 513.4 455.9 Equity & Liabili
Slide 12: Cash Flow Statement
Cash Flow Statement Particulars (Rs. Cr) FY19 FY20 FY21 FY22 FY23 Profit before tax 336.15 533.24 571.39 222.84 189.49 Adjustments for: Non Cash Items / Other Investment or 82.35 51.93 27.15 33.12 44.42 Financial Items Operating profit before working capital changes 418.50 585.17 598.54 255.96 233.9
Slide 13: 5-years Performance
5-years Performance Operational Revenue (Rs Cr) EBITDA (Rs Cr) and EBITDA Margin (%) PAT (Rs Cr) and PAT Margin (%) 2,216 2,243 30.9% 30.9% 22.3% 1,911 1,991 18.9% 1,696 24.8% 13.0% 14.0% 990 12.7% 11.2% 7.5% 6.2% 2.8% 126 420 590 616 288 252 28 237 361 445 166 140 FY18 FY19 FY20 FY21 FY22 FY23 FY18
Slide 14: Diversified revenue base
Diversified revenue base FY18 FY23 Q1 FY24 362, 37% 955, 43% 214, 38% 35, 3% 476, 22% 124, 22% 586, 60% 786, 35% 225, 40% Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's 14 * Amt in Rs.crore
Slide 15: Company Overview
COMPANY OVERVIEW
Slide 16: The Journey
The Journey ▪ 2009 - Commencement of ▪ 2015 - USFDA, EIR for ▪ 2019 - Unit-06 for ▪ 1996 - Commencement of IBB, MCA and Acetyl ▪ Commenced Ibuprofen Pantoprazole (Dedicated) Ethyl Acetate Plant Chloride Plants commercial production ▪ 2016 - Unit-03 for new ▪ 2020 - Unit-07 Metformin ▪ 1999 - Commenc
Slide 17: Core management team
Core management team Varinder Gupta (Managing Director) ▪ Wide and rich experience of more than 35 years in the chemical & fertilizer industry and along Vikas Gupta with a comprehensive approach and strong (Joint Managing Director) Pharma API industry oversight has paved a way ▪ Academically equippe
Slide 18: Board of Directors
Board of Directors Rajender Mohan Malla (Chairman and Independent Director) ▪ With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs Harpal Singh ▪ In his most recent executive roles, he was MD & (Independent Director) CEO of PTC I
Slide 19: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility since EUGMP Certification in 2013, Certificate of Suitability from Certified Halal in accordance 2015, recertified in 2019 2017 & Recertification in 2020 Certificate of DMF Registration EDQM with Shariah Board Guidelines From MFDS Korea Certi
Slide 20: Business Overview
BUSINESS OVERVIEW
Slide 21: Pharmaceuticals – Building API portfolio
Pharmaceuticals – Building API portfolio IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen having a capacity of 12000+ MT • Dedicated USFDA approved facilities for Ib
Slide 22: Specialty chemicals – capitalizing on global demand
Specialty chemicals – capitalizing on global demand IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 TPA Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 TPA • India’s se
Slide 23: Manufacturing facilities
Manufacturing facilities API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC 1 3 5 intermediates & Specialty chemicals in Dedicated and multiproduct blocks system, PSA Nitrogen & Purified water continuous product delivery manner involved in manufacturing of APIs along with
Slide 24: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives Environment • Committed to ensure that our operations have minimal • Our continuous efforts have resulted in a 4.58% impact on the environment • Constantly monitoring environmental footprints and reduction in Scope-01 greenhouse gas (GHG) emiss
Slide 25: Industry Overview
INDUSTRY OVERVIEW
Slide 26: Pharmaceuticals – Emerging strongly out of pandemic
Pharmaceuticals – Emerging strongly out of pandemic Indian API Market World Pharmaceutical Industry • Pharmaceutical exports have registered a 3.25 per cent growth in FY23 at $25.3 billion. In 2021-22, the exports growth was almost flat at 0.71 per cent at $24.62 billion $1.5 3-6% $2.4 Trillion (202
Slide 27: Specialty Chemicals - an era of sustained robust growth
Specialty Chemicals - an era of sustained robust growth • India is expected to become a $850-1000 Bn chemicals market by 2040, taking 10-12% share of the global Indian Specialty Chemical Industry chemicals market • The sector is projected to grow at 11-12% during 2021- Specialty 27 and 7-10% during
Slide 28: Way Forward
WAY FORWARD
Slide 29: Charting a path to success
Charting a path to success Four pronged strategy for growth Focus on Capacity Improved Expanding Regulated expansion in asset Non-Ibuprofen Markets Pharma & utilization Business Chemicals During the last five years During the last five years, Increased contribution Added more than 10 the share of re
Slide 30: Expanding the non-Ibuprofen business
Expanding the non-Ibuprofen business (Analgesic and Antipyretic drugs) Multi Product facility focused on Paracetamol, with an Regulatory Filings: CEP installed capacity of approved; US DMF filed 3,600 MT/Annum, with a backward integration process (Antiplatelet drug, used in cardiovascular (Anticonsu
Slide 31: Summary
Summary Pharmaceutical Segment • Moving towards a well diversified product portfolio, that is a shift towards the non-ibuprofen business. • We have successfully implemented manufacturing processes for Pantoprazole, Clopidogrel, Levetiracetam, and other APIs. • Our creation of synergistic segments, s
Slide 32: Thank You
Thank You Company : Investor Relations Advisors : IOL Chemicals & Adfactorspr Pvt. Ltd. Pharmaceuticals Ltd. Mr. Pardeep Kumar Khanna, Darshan Mankad CFO darshan.mankad@adfactorspr.com pardeepkhanna@iolcp.com Hanishi Shah hanishi.shah@adfactorspr.com www.iolcp.com www.adfactorspr.com
IOL Chemicals and Pharmaceuticals — Q1 FY24 Earnings Presentation on 6ix